Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

HUTCHMED

HUTCHMED

HCM

0.00

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ: HCM) with a Neutral and lowers the price target from $16 to $14.